About
Darling Therapeutics is a preclinical-stage pharmaceutical company currently focused on addressing rare diseases via gene therapies.  The long-term vision is to become publicly traded via a Direct Listing with Capital Raise and to move from metabolic rare diseases to neurologic rare diseases over time.  Darling Therapeutics is putting together a strong set of documents and training modules in advance of funding to lay the foundation to recruit the best of the best to help build a great company rooted in strong values.  We have an IRS EIN (88-2546870) and are both a registered company trading under Darling Therapeutics Ltd in London, England and a registered company trading under Darling Therapeutics LLC in San Francisco, California.
Back to Top